iBio (IBIO) grants 13,500 stock options to director at $1
iBio, Inc. (IBIO) reported a director equity award on a Form 4.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
iBio, Inc. (IBIO) reported a director equity award on a Form 4. On 11/20/2025, the reporting person received a stock option grant covering 13,500 shares of iBio common stock. The options have an exercise price of $1 per share and an expiration date of 11/19/2035.
The filing states that these options vest on a pro rata basis each month over twelve months, starting on the grant date. Following this grant, the reporting person beneficially owns 13,500 derivative securities directly in the form of these options.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 13,500 | $0.00 | $0.00 |
Footnotes (1)
- F1. These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did iBio (IBIO) report in this Form 4?
What is the exercise price and term of the new iBio (IBIO) stock options?
How do the iBio (IBIO) director stock options vest?
How many derivative securities does the iBio (IBIO) director beneficially own after this transaction?
What type of security was granted to the iBio (IBIO) director?
AI-generated analysis. How Rhea-AI works. Not financial advice.